B. Riley lowered the firm’s price target on Viridian Therapeutics (VRDN) to $19 from $22 and keeps a Neutral rating on the shares. Amgen’s (AMGN) softer Tepezza numbers suggest the thyroid eye disease market may be under $2B and possibly shrinking, as most prevalence-related demand has likely been met and new use will depend on ongoing incidence, the analyst tells investors in a research note. A successful outcome of the readout for VRDN-003 could unlock value for shareholders, the firm says.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Strategic Developments and Strong Financial Position Justify Buy Rating
- Viridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data
- Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP
- Viridian Therapeutics Reports Q1 2025 Progress and Financials
- Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating